| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e41eefe437d41c6b293dbdc3abd7297f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-304
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2570-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34 |
| filingDate |
2016-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07fe3655fe650ea096620d64a7d10b23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d4035f120cec32b91e39521291a2e76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3d9c9a26bfa6f07ab842146cfe1ee1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf6db580e3920d7defc5519c6ab0eb58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c4fdafa16b8ea68fa3df381731427ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b1c246ec2cfe58f2acc5ffc2272728a |
| publicationDate |
2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10309967-B2 |
| titleOfInvention |
Methods of diagnosing bipolar disorders and screening for therapeutic compounds |
| abstract |
Methods of diagnosing, confirming a diagnosis of, and determining a predisposition for a bipolar disorder in a subject are provided. An amount of at least one of biomarker from the cerebrospinal fluid and/or serum of a subject is measured, for example, isocitric acid. The amount of the at least one biomarker can be compared with a control amount of the at least one biomarker in a corresponding sample collected from a subject without the bipolar disorder. An increase or decrease in the amount of the particular biomarker or biomarkers measured can be indicative that the subject has the bipolar disorder or a predisposition for the bipolar disorder. Methods of identifying a compound for preventing and/or treating a bipolar disorder are also provided based on the expression level of an isocitric acid dehydrogenase 3 alpha and/or beta-subunit gene, and/or based on one or more metabolite biomarker. |
| priorityDate |
2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |